Dose-Response Effect of Fruit and Vegetables on Insulin Resistance in People at High Risk of Cardiovascular Disease

A randomized controlled trial

OBJECTIVE—The purpose of this randomized controlled trial was to investigate the dose-response effect of fruit and vegetable (F&V) intake on insulin resistance (IR) in people who are overweight and at high risk of cardiovascular disease (CVD).

RESEARCH DESIGN AND METHODS—A total of 105 participants (mean age 56 years) followed a 4-week washout diet (one to two portions of F&Vs per day). Ninety-two participants completed the washout and were randomized to receive one to two, four, or seven portions of F&Vs per day for 12 weeks. IR was assessed at the start and end of this 12-week period by the two-step euglycemic-hyperinsulinemic clamp. Compliance was monitored using a combination of 4-day food diaries and plasma biomarkers of F&V intake.

RESULTS—A total of 89 participants completed the study. Participants attained self-reported F&V intakes of 1.8, 3.8, and 7.0 portions per day ($P < 0.001$) per group. There was a significant linear increase in serum lutein status across the groups, indicating good compliance ($P < 0.001$), and body weight was maintained ($P = 0.77$). No significant difference was found between groups in terms of a change in measures of whole-body, peripheral, or hepatic IR or adiponectin multimers.

CONCLUSIONS—Increased consumption of F&Vs, as advocated in public-health advice, has no effect on IR in overweight individuals who are at high risk of CVD when body weight is maintained. Recent evidence from systematic reviews indicates that particular classes or types of F&Vs may have particular antidiabetic properties; hence, it is possible that benefits may only be observed in response to a more specific fruit or vegetable intervention.

Insulin resistance (IR) is a central feature of the metabolic (or insulin-resistance) syndrome and is a key predictor of the development of type 2 diabetes and cardiovascular disease (CVD) (1). Because IR develops before vascular disease becomes apparent, interventions that prevent or reverse IR may help to attenuate the risk of CVD and type 2 diabetes.

Observational evidence indicates that fruit and vegetable (F&V) intake and dietary patterns rich in F&Vs may be associated with reduced IR and may reduce the risk of the metabolic syndrome (2,3). Cross-sectional evidence indicates an inverse association among biomarkers of F&V intake, carotenoid and vitamin C status, fasting plasma glucose concentrations (4), fasting serum insulin concentrations (5), HbA1c levels (6), and fasting and 2-h blood glucose levels (6). Furthermore, whole diet interventions using diets rich in F&Vs, such as the DASH (Dietary Approaches to Stop Hypertension) diet (7,8) and the Mediterranean diet (9,10), have been shown to have beneficial effects on IR, features of the metabolic syndrome, and prevention of diabetes. Esposito et al. (9) reported a significant decrease in IR (assessed by homeostatic model assessment [HOMA]), and a reduction in the prevalence of the metabolic syndrome, after a 2-year Mediterranean-style diet intervention in 180 patients with the metabolic syndrome. Evidence from observational studies and whole diet interventions rich in F&Vs therefore suggests that F&Vs may have a positive influence on IR and metabolic health. The low energy density and high dietary fiber, antioxidant, and bioactive content of F&Vs, and their potential to displace less desirable foods from the diet, have all been proposed as potential mediators of this association between F&Vs and IR (11).

The World Health Organization recommends consumption of 400 g of F&Vs per day for the prevention of noncommunicable diseases including CVD and type 2 diabetes; however, little is known about the metabolic effects of F&Vs. In order to help inform public health strategies for the prevention of CVD and type 2 diabetes, a prospective investigation of the effect of F&V intake on insulin action in vivo is warranted. The aim of this study was to investigate the dose-response effect of F&V intake on IR, assessed using the gold standard euglycemic-hyperinsulinemic clamp technique, in people who were overweight and at high risk of CVD.
RESEARCH DESIGN AND METHODS

Study overview
Ethics approval for this randomized controlled trial (RCT) was received from the Office for Research Ethics Committees Northern Ireland, and the study protocol was registered (ClinicalTrials.gov, NCT00874341). The study used a 4-week washout period to minimize pretreatment biochemical and/or physiological disparities. After the washout phase, participants were informed of their allocation to one of the following three F&V groups for 12 weeks: one to two, four, or seven portions of F&Vs each day. The primary end point, IR, was measured using the two-step euglycemic-hyperinsulinemic clamp technique at week 4 and week 16 (preintervention and postintervention).

Participant recruitment and screening
Between April 2009 and February 2011, participants were recruited from the general population via press release, by intranet advertisements within Belfast Health and Social Care Trust and Queen’s University Belfast, and from hospital outpatient clinics. Interested participants were screened for eligibility. The inclusion criteria were as follows: CVD risk of ≥20% over 10 years, as defined by Joint British Societies’ guidelines on the prevention of CVD in clinical practice (12); BMI ≥27 and ≤35 kg/m², and habitual F&V intake of two or fewer portions per day. The exclusion criteria were as follows: diabetes mellitus; established CVD; surgery within the previous 3 months; aspirin use; psychiatric problems; taking medication known to affect nutrient metabolism; pregnant or lactating; excessive alcohol consumption; taking antioxidant supplements; food sensitivities that would interfere with a tolerance to F&Vs; medical conditions or dietary restrictions that would substantially limit the ability to complete the study requirements; following a weight loss diet; unwillingness or inability to modify current diet; and women of childbearing age not taking the contraceptive pill.

Washout phase (week 0–4)
After eligibility was confirmed and written informed consent was obtained, all participants commenced the washout and were asked to consume less than two portions of F&Vs per day for 4 weeks. Participants were given an information booklet to ensure that they understood the requirement to consume less than two portions of F&Vs per day and the definition of what constitutes a portion of F&Vs, as defined by the U.K. Department of Health (13) (i.e., an 80-g serving: one apple or banana, 150 mL fruit juice or 3 heaping tablespoons of vegetables).

Intervention phase (week 4–16)
Participants were randomized at study entry and were informed of their randomization allocation at week 4 (i.e., after they had completed the washout period). A computer-generated randomization list was used to allocate participants to one of the following three intervention groups: one to two, four, or seven portions of F&Vs per day; owing to the nature of the intervention it was not possible to blind participants to their allocation. All participants were provided with written dietary advice specific to their allocated F&V group, which detailed portion sizes of F&Vs and provided guidance on cooking and storage, as well as recipe suggestions and general tips on eating more F&Vs. Participants in the four- and seven-portion groups were provided with individualized advice on ways to incorporate F&Vs into daily meals, taking into consideration normal meal/snack patterns, habitual F&V likes and dislikes, and any identified barriers/constraints to F&V consumption. In order to encourage compliance, participants received a weekly home delivery of F&Vs from a major retailer for the duration of the intervention. The study researcher telephoned participants on a weekly basis in order to discuss their F&V order, monitor compliance and body weight, and discuss any individual difficulties with adherence to the protocol. In line with public health advice, participants were encouraged to consume as wide a variety of F&Vs as possible. Compliance was monitored using a combination of self-reported dietary intake (4-day food diaries at weeks 0, 4, and 16; at least four unannounced 24-h recalls during the intervention period; and daily F&V records) and biochemical assessment of nutritional status, as described below.

F&V portions consumed by each participant at the three time points during the intervention (weeks 0, 4, and 16) were hand counted independently by two researchers from the 4-day food diaries, and any discrepancies were assessed and resolved with input from a third researcher. A portion was as defined by the U.K. Department of Health (13).

Study assessments
Assessments were carried out at the Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast. A medical/lifestyle questionnaire and a physical activity questionnaire were administered at weeks 0 and 16 (14).

Height, weight, and waist and hip circumferences were measured at weeks 0, 4, and 16. Body composition was measured using a whole-body dual-energy X-ray absorptiometry scan at weeks 4 and 16. All scans were performed by a trained radiographer using a Lunar Prodigy Pro dual-energy X-ray absorptiometry scanner (GE Medical Systems, Madison, WI). Blood pressure at week 4 was measured using an oscillometric Meditech ABPM-04 ambulatory BP system [P.M.S. (Instruments) Ltd, Berkshire, U.K.].

At two-step euglycemic-hyperinsulinemic clamp combined with the infusion of [3–3H]glucose was carried out at weeks 4 and 16 by I.R.W., who was blinded to group allocation, as previously described (15,16). After cannula insertion, a primed continuous infusion of high-performance liquid chromatography–purified [3–3H]glucose was administered during a 2-h equilibration period (−120 min to zero time). ArtIALIZED venous blood was used for all analyses in the clamp studies. Plasma for the measurement of glucose-specific activity was deproteinized with barium hydroxide and zinc sulfate using the method of Somogyi (17). Aliquots of tracer infusate and labeled exogenous glucose infusion were spiked into nonradioactive plasma and processed in parallel to allow the calculation of [3–3H]glucose infusion rates (GIRs). IR was assessed using the exogenous GIR required to maintain euglycemia corrected for body weight and for fat-free body mass. The isotope-dilution method was used to allow the measurement of endogenous glucose production (EGP), the rate of appearance of glucose in the peripheral circulation (Ra), and the rate of disappearance or whole body uptake of glucose (Rd).

Indirect calorimetry was performed alongside the two-step clamp at weeks 4 and 16. An open-circuit indirect calorimeter (GEMNutrition Ltd., Daresbury, U.K.) with a ventilated canopy hood was used to measure minute-by-minute oxygen consumption and carbon dioxide production. Resting energy expenditure was measured during the last 45 min of the calibration period (~45 min to zero time), after participants rested for a minimum of 75 min. Energy expenditure was
Fruit, vegetables, and insulin resistance

also measured during the final stages of the low-dose insulin infusion (90–120 min) and the high-dose insulin infusion (210–240 min). Insulin-induced thermogenesis during the low-dose and high-dose insulin infusions was calculated as the difference between energy expenditure measured during each insulin infusion and the resting energy expenditure (18). Change in the respiratory quotient (RQ), calculated as the RQ during the high-dose insulin infusion minus the resting RQ (19), was used as an indicator of metabolic flexibility.

**Laboratory analysis**

A fasting blood sample was collected at weeks 0, 4, and 16. All samples were processed and stored at −80°C within 2 h of collection. All laboratory analyses were blinded. Plasma ascorbic acid concentrations were determined according to the method described by Vuilleumier and Keck (20). Serum concentrations of lutein, zeaxanthin, β-cryptoxanthin, α-carotene, β-carotene, and lycopene were measured by high-performance liquid chromatography with diode array detection, as described by Craft et al. (21). Assays were standardized against appropriate National Institute of Standards and Technology control materials. The fasting serum lipid profile (total cholesterol, HDL, and triglycerides) was assessed using enzymatic colorimetric assays (Roche Diagnostics Limited, West Sussex, U.K.) on the ILab-600 biochemical analyzer (Instrumentation Laboratory, Warrington, U.K.). LDL cholesterol was calculated using a standard Friedewald equation (22). Plasma adiponectin (total, high-molecular weight, medium-molecular weight, and low-molecular weight) was measured by ELISA (ALPCO diagnostics); low-molecular weight adiponectin was obtained by subtracting the combined concentration of medium-molecular weight and high-molecular weight adiponectin (measured directly) from the total adiponectin concentration. Serum insulin levels were measured by ELISA (Abbot IMx; Abbott Laboratories, Berkshire, U.K.). Plasma glucose levels were measured using an automated glucose oxidase method using a Beckman Glucose Analyzer 2. Fasting glucose and insulin levels were used to calculate the HOMA score (23). Commercial kits were used to measure C-peptide (Dako UK Ltd, Ely, U.K.) and nonesterified fatty acids (Wako Chemicals GmbH, Neuss, Germany) on the ILab-600 biochemical analyzer (Instrumentation Laboratory).

**Statistical methods**

All statistical analyses were carried out using SPSS for Windows version 17.0 (SPSS Inc, Chicago, IL). Normally distributed continuous variables were summated using the mean and SD. Skewed variables were log-transformed for parametric analysis and summarized using the geometric mean and interquartile range. A one-way ANOVA test, or χ² test, was used to compare the three groups at baseline for continuous and categorical variables, respectively. One-way ANOVA with linear trend test was used to examine differences in mean change (i.e., preintervention value minus postintervention value for a given continuous variable) between groups for the primary and secondary end points. Post hoc analyses were performed using the Dunnett test comparing the control group (one to two portions) with the intervention groups (four and seven portions). For each variable, intervention analysis was performed for all participants who had completed the study protocol according to randomization group. The test for linear trend (with changes in variable and portion allocation as the dependent and independent variables, respectively, analogous to linear regression, was incorporated in order to take account of the dose-response design. Variables that were not normally distributed were log-transformed prior to these analyses. A sample size of 30 patients per group gave the study 80% power to detect a 10% difference in GIR between groups at a 5% level of significance (15,16).

**RESULTS**—Summary of participant recruitment and flow through the intervention (Supplementary Fig. 1). In total, 150 individuals were screened for eligibility, and 45 did not meet study eligibility criteria. A total of 105 participants commenced the 4-week washout period of the study (weeks 0–4). There were 13 dropouts (12.4%) between weeks 0 and 4 (reasons are indicated in Supplementary Fig. 1). A total of 92 participants proceeded to the intervention phase of the study (weeks 4–16), and 89 participants completed the 16-week protocol. There were three dropouts between weeks 4 and 16: one from the group receiving one to two F&V portions per day and two from the group receiving four F&V portions per day, all owing to illness unrelated to the intervention. The intervention was implemented as intended, and there were no adverse events associated with the intervention. Of the 105 eligible participants who consented to join the study (n = 105) at week 0, 64% were male (n = 61), two-thirds were obese (n = 67), and one-third were overweight (n = 38).

**Washout phase (week 0–4)**

The washout phase resulted in a statistically significant lowering in F&V intake from a mean of 2.4 (SD 1.11) portions per day at week 0 to a mean of 1.6 (SD 0.85) portions per day at week 4 (P < 0.001; independent-samples t test; data not shown). These changes were accompanied by a statistically significant decrease in plasma vitamin C, lutein, β-cryptoxanthin, and α-carotene status (P < 0.05; independent-samples t test; data not shown).

**Intervention phase (week 4–16)**

The baseline characteristics of all participants who completed the washout and commenced the intervention (n = 92) at week 4 are presented in Supplementary Table 1. There were no statistically significant differences between the groups at the start of the intervention. The majority of participants (72%) were categorized as inactive or moderately inactive, 18% as moderately active, and 10% as active. The goal of maintaining body weight during the study was achieved; there were no statistically significant mean differences in change in body weight or body composition (data not shown) among the groups receiving one to two, four, and seven F&V portions, respectively, as follows: 0.41% change in body weight (95% Cl −0.29 to 1.12); 0.38 (−0.01 to 1.17; 0.33 (−0.20 to 0.85) (P = 0.82, one-way ANOVA). There was no significant change in physical activity within or among groups during the study (data not shown).

F&V intake and micronutrient status. There was a statistically significant linear change in daily F&V consumption among the three groups (Table 1), based on self-reported F&V intake calculated from 4-day food diaries. Participants in the groups receiving one to two, four, and seven F&V portions per day attained self-reported F&V intakes of 1.8, 3.8, and 7.0 portions per day, respectively; this represented no significant change in the two-portion group and a statistically significant increase in F&V intake of 2.1 and 5.5 portions per day within the groups receiving four and seven portions per day, respectively (P < 0.0001, paired-samples t test). There was a statistically significant linear increase in lutein status with increasing F&V intake, and a nonsignificant trend for increasing...
Between-group changes were compared using a test for linear trend. Data are mean (SD), except for change, which is mean (95% CI) of differences between week 4 and week 16 values. *One portion of F&Vs = 80 g, as defined by the U.K. Department of Health.

### Table 1—F&V intake at week 4 (preintervention) and week 16 (postintervention) according to F&V allocation

| F&V’s   | Week 4 | Week 16 | Change |
|---------|--------|---------|--------|
|         | Amount (g) | Amount (g) |        |
| Two portions/day (n = 26 maximum) | 1.71 (1.00) | 1.76 (0.47) | 0.05 (−2.38 to 0.48) |
| Four portions/day (n = 23 maximum) | 3.40 (0.98) | 2.10 (1.0) | 1.30 (−2.66 to 0.48) |
| Seven portions/day (n = 23 maximum) | 7.06 (1.51) | 5.50 (4.97–6.03) | <0.0001 |

### CONCLUSIONS

Current dietary recommendations for F&V consumption are based on observational evidence regarding the relationship between these foods and the risk of chronic disease. Recently, data regarding the precise nature of their biological effects have started to emerge from RCTs (24). Such studies in both healthy and clinical groups are important in order to inform public health messages and evidence-based clinical practice. The RCT described here is the first to examine the cause-effect plausibility of a dose-response relationship between F&V consumption and IR, assessed using the comprehensive glucose clamp technique, in people at high risk of CVD. Despite objective evidence of compliance with the intervention, increased F&V intake did not have a statistically significant effect on whole-body, peripheral, or hepatic IR or concentrations of adiponectin multimers. A favorable effect on microvascular function, assessed by venous occlusion plethysmography, has recently been demonstrated in another dose-response F&V intervention study (24). There is a recognized reciprocal relationship between IR and endothelial dysfunction (23), and it could be hypothesized that the beneficial effects of F&V on vascular function may be mediated by improvements in IR. The results of this RCT do not support this notion; furthermore, the change in vascular function in the aforementioned study did not correlate with the change in HOMA (26). Taken together, these results indicate that the beneficial effects of F&Vs in relation to cardiovascular health are not likely to be directly mediated by IR.

It is well-accepted, after the diabetes prevention trials, that weight loss can improve glucose tolerance and help to prevent type 2 diabetes (27,28); positive effects on body weight and overall dietary profile are recognized as one potential way in which F&Vs may reduce the risk of chronic disease (29). However, it is also possible that F&Vs may have subtle effects on IR, on body weight, F&Vs may not have a direct effect on the risk of type 2 diabetes (29). It is possible that, independent of potential effects on body weight, F&Vs may have subtle effects on IR, which are only detectable in a normal-weight insulin-resistant group, or in overweight or obese populations after substantial weight loss has occurred. Moreover, although this study was conducted in a population at high risk of CVD, the majority of participants did not have impaired fasting glucose levels, and the effects may be different in a group of participants with prediabetes.

Displacement of less desirable foods, resulting in an improved dietary profile, has been discussed as a possible explanation for the beneficial effect of F&Vs on cardiovascular risk. In this study,
Table 2—Micronutrient status at week 4 (preintervention) and week 16 (postintervention) according to F&V allocation

| Micronutrients (µmol/L) | Two portions/day | Change | Four portions/day | Change | Seven portions/day | Change | P‡ for trend‡ |
|-------------------------|------------------|--------|-------------------|--------|-------------------|--------|-------------|
|                         | Week 4 (n = 28 maximum) |       | Week 4 (n = 29 maximum) |       | Week 4 (n = 28 maximum) |       |             |
| Vitamin C               | 32.3 (21.8)      |        | 33.1 (20.1)       |        | 33.7 (20.4)       |        |             |
|                         | 36.4 (23.8)      |        | 49.7 (23.1)       |        | 50.0 (20.1)       |        |             |
|                         | 3.1 (–4.4 to 10.7) |       | 16.5 (5.4–27.7)   |        | 16.4 (7.9–24.8)   |        |             |
| Lutein                  | 0.16 (0.09)      |        | 0.14 (0.04)       |        | 0.14 (0.06)       |        |             |
|                         | 0.17 (0.08)      |        | 0.17 (0.07)       |        | 0.19 (0.10)       |        |             |
|                         | 0.00 (–0.01 to 0.02) |      | 0.02 (0.01–0.04)  |        | 0.05 (0.02–0.07)  |        |             |
| Zeaxanthin              | 0.04 (0.021)     |        | 0.039 (0.016)     |        | 0.051 (0.056)     |        |             |
|                         | 0.046 (0.019)    |        | 0.046 (0.020)     |        | 0.052 (0.026)     |        |             |
|                         | 0.003 (–0.002 to 0.008) |    | 0.007 (0.000–0.014) |        | 0.001 (–0.017 to 0.019) |        |             |
| B-Cryptoxanthin*        | 0.07 (0.05–0.09) |        | 0.07 (0.04–0.11)  |        | 0.08 (0.04–0.10)  |        |             |
|                         | 0.08 (0.06–0.12) |        | 0.10 (0.07–0.15)  |        | 0.10 (0.07–0.18)  |        |             |
|                         | 1.09 (0.94–1.27) |        | 1.39 (1.15–1.69)  |        | 1.35 (1.08–1.69)  |        |             |
| α-Carotene*             | 0.04 (0.03–0.06) |        | 0.03 (0.02–0.05)  |        | 0.05 (0.03–0.05)  |        |             |
|                         | 0.04 (0.03–0.06) |        | 0.04 (0.03–0.07)  |        | 0.05 (0.04–0.09)  |        |             |
|                         | 1.03 (0.89–1.20) |        | 1.33 (1.07–1.65)  |        | 1.14 (0.94–1.38)  |        |             |
| B-Carotene*             | 0.22 (0.15–0.36) |        | 0.20 (0.13–0.35)  |        | 0.23 (0.14–0.37)  |        |             |
|                         | 0.22 (0.14–0.37) |        | 0.23 (0.15–0.38)  |        | 0.28 (0.16–0.48)  |        |             |
|                         | 1.00 (0.90–1.11) |        | 1.13 (0.94–1.35)  |        | 1.22 (1.04–1.44)  |        |             |
| Lycopene*               | 0.67 (0.29–1.17) |        | 0.43 (0.24–0.59)  |        | 0.52 (0.33–0.65)  |        |             |
|                         | 0.80 (0.42–1.23) |        | 0.44 (0.27–0.67)  |        | 0.71 (0.41–0.94)  |        |             |
|                         | 1.20 (0.97–1.48) |        | 1.01 (0.81–1.27)  |        | 1.36 (0.74–2.50)  |        |             |
|                         |                  |        |                   |        |                   |        |             |

Data are mean (SD), except for change, which is mean (95% CI) of differences between week 4 and week 16 values unless otherwise stated. *Skewed variable log-transformed for analysis and summarized as geometric mean (interquartile range) and change as geometric mean (95% CI) of the ratio of week 16 to week 4 values. †Between-group comparisons analyzed using a one-way ANOVA test. ‡Between-group comparisons analyzed using a test for linear trend.
Table 3—Fasting insulin (pmol/L)*

|                | Week 4 | Week 16 | Change |
|----------------|--------|---------|--------|
| Two portions/day | 1.08   | 0.94    | 0.14   |
| Four portions/day | 1.03   | 0.90    | 0.13   |
| Seven portions/day | 1.02   | 0.89    | 0.13   |

n = 28, 29, 30;

*Data are mean (SD), except for change, which is mean (95% CI) of differences between week 4 and week 16 values unless otherwise stated. FFM, fat-free mass.
Table 4—Glucose production and glucose uptake at week 4 (preintervention) and week 16 (postintervention) according to F&V allocation

| Variables    | Two portions/day |        |        | Four portions/day |        |        | Seven portions/day |        |        |        | P† | P for trend‡ |
|--------------|------------------|--------|--------|------------------|--------|--------|-------------------|--------|--------|--------|----|-------------|
|              | Week 4       | Week 16 | Change | Week 4           | Week 16 | Change | Week 4           | Week 16 | Change |         |    |             |
| Ra basal     |               |        |        |                  |        |        |                  |        |        |         |    |             |
| (μmol/kg/min) | (n = 28, 29, 30)|        |        |                  |        |        |                  |        |        |         |    |             |
|              | 10.1 (1.3)    | 10.9 (1.4) | 0.9 (0.4–1.4) | 11.0 (2.6) | 10.2 (2.7) | –0.7 (–1.7 to 0.2) | 10.2 (1.5) | 10.5 (2.0) | 0.3 (–0.6 to 1.1) | 0.02 | 0.30 |
| Ra step 1    | (μmol/kg/min)* | (n = 25, 24, 29) |        |                  |        |        |                  |        |        |         |    |             |
|              | 13.3          | 13.1 | 0.98 | 12.3 | 10.9 | 0.88 | 13.1 | 13.7 | 1.04 | 0.12 | 0.39 |
| Ra step 2    | (μmol/kg/min)* | (n = 28, 29, 30) |        |                  |        |        |                  |        |        |         |    |             |
|              | 38.4          | 38.9 | 1.01 | 37.7 | 36.1 | 0.96 | 38.0 | 36.9 | 0.97 | 0.56 | 0.44 |
| EGP basal    | (μmol/kg/min) | (n = 28, 29, 31) |        |                  |        |        |                  |        |        |         |    |             |
|              | 10.1 (1.3)    | 10.9 (1.4) | 0.9 (0.4–1.4) | 11.0 (2.6) | 10.2 (2.7) | –0.7 (–1.7 to 0.2) | 10.2 (1.5) | 10.5 (2.0) | 0.3 (–0.5 to 1.2) | 0.02 | 0.37 |
| EGP step 1   | (μmol/kg/min) | (n = 25, 24, 29) |        |                  |        |        |                  |        |        |         |    |             |
|              | 5.6 (2.6)     | 5.9 (2.5) | 0.4 (–0.9 to 1.7) | 5.8 (2.6) | 5.0 (1.9) | –0.9 (–2.2 to 0.4) | 5.1 (1.7) | 5.5 (2.1) | 0.4 (–0.4 to 1.3) | 0.18 | 0.86 |
| EGP step 2   | (μmol/kg/min) | (n = 28, 29, 30) |        |                  |        |        |                  |        |        |         |    |             |
|              | 3.6 (2.7)     | 5.4 (3.1) | 1.8 (0.5–3.1) | 5.4 (3.8) | 3.1 (2.4) | –2.3 (–4.1 to –0.6) | 3.5 (3.2) | 4.2 (3.5) | 0.7 (–1.1 to 2.5) | 0.002 | 0.37 |
| Rd basal     | (μmol/kg/min) | (n = 28, 29, 30) |        |                  |        |        |                  |        |        |         |    |             |
|              | 10.1 (1.3)    | 10.8 (1.3) | 0.7 (0.2–1.2) | 11.0 (2.5) | 10.2 (2.6) | –0.7 (–1.7 to 0.2) | 10.2 (1.4) | 10.4 (1.8) | 0.2 (–0.6 to 0.9) | 0.02 | 0.34 |
| Rd step 1    | (μmol/kg/min)* | (n = 25, 24, 29) |        |                  |        |        |                  |        |        |         |    |             |
|              | 13.5          | 12.7 | 0.94 | 12.2 | 11.1 | 0.91 | 13.1 | 13.8 | 1.05 | 0.07 | 0.08 |
| Rd step 2    | (μmol/kg/min)* | (n = 28, 29, 30) |        |                  |        |        |                  |        |        |         |    |             |
|              | 38.3          | 38.6 | 1.01 | 37.9 | 36.2 | 0.96 | 38.0 | 37.1 | 0.98 | 0.64 | 0.67 |

Data are mean (SD), except for change, which is mean (95% CI) of differences between week 4 and week 16 values unless otherwise stated. *Skewed variable logarithmically transformed for analysis and summarized as geometric mean (interquartile range) and change as geometric mean (95% CI) of the ratio of week 16 to week 4 values. †Between-group comparisons analyzed using a one-way ANOVA F test. ‡Between-group comparisons analyzed using a test for linear trend.
ate more vegetables because the behavior within groups was quite consistent; all individuals in the group receiving seven portions per day consumed more fruit than vegetables. With regard to the increase in fruit intake, it is important to note that, in line with current public health advice, participants were informed that fruit or vegetable juice could only count as one of their F&V portions daily, and so they were advised to limit their juice consumption accordingly and to increase their intake of F&Vs by consuming the intact food rather than relying on fruit or vegetable juice to boost their intake. Adherence to this advice was evident in the participant food diaries, and there were no high juice consumers in the study. As discussed above, because this study did not restrict the types or proportions of F&Vs consumed, there were significant differences among groups in change in sugar intake, and other factors such as glycemic index and glycemic load are also likely to have changed, although this has not been formally examined. Again, a more prescriptive intervention controlling for such variables may provide a different answer to the one found here. Because this study did not control for the type of F&V or the relative proportion of fruit versus vegetables to be consumed by participants, it cannot answer questions regarding the appropriateness of more specific guidance on F&V intake; rather, this study examined the implementation of the general message promoted in the U.K. and the U.S. to eat a variety of F&Vs each day, generally aiming for at least five servings a day. It is interesting to note that public health guidance in Australia advocates a two-fruit-plus-five-vegetable approach in their guidance to consumers (35). It is likely that public health advice in other countries may, similarly, evolve over time to become more specific. However, there are a limited number of studies to date regarding the importance of F&V variety for health outcomes or examining the specific health effects of fruit versus vegetables (36).

Apart from the current study, to our knowledge, no other study to date has specifically examined the effect of whole F&Vs on IR using the gold standard clamp methodology. A recent double-blind, randomized, placebo-controlled study in 32 obese, insulin-resistant men and women found that intake of 22.5 g of blueberry bioactives twice daily for 6 weeks enhanced insulin sensitivity, which was assessed using high-dose euglycemic-hyperinsulinemic clamp, compared with placebo, perhaps suggesting that the form in which F&Vs are consumed may be important in terms of antidiabetic effects (37). The latter study, however, does not help to inform public health messages about F&V consumption inasmuch as a freeze-dried blueberry powder was used rather than the whole food or juice. Allowing volunteers to make their own dietary choices, as was applied in this protocol, is closer to the current real-life scenario where people receive general advice to “eat more F&Vs.”

A threshold effect beyond the maximum portion allocation used here (seven portions per day) is unlikely based on the existing literature (11) but cannot be excluded. However, even if such a threshold exists, an intake higher than seven portions per day would be unattainable for the vast majority of the population.

The strengths of the current study include itsRCT design; the use of the clamp to assess the primary end point; high participant retention; the weight stability of participants, which prevented confounding of the data by weight loss; and the measurement of biomarkers of F&V intake. In this study, the self-reported F&V intakes, derived from food diaries, were consistent with group targets for participants in the groups receiving one to two, four, and seven portions per day attaining self-reported F&V intakes of 1.8, 3.8, and 7.0 portions per day, respectively. This change in self-reported F&V intake was mirrored by a statistically significant dose-response increase in lutein status with increasing F&V intake and a trend for increasing vitamin C and β-carotene status, thus confirming that the volunteers did increase their F&V intake in a stepwise manner across groups. As indicated in our recent systematic review on this topic (38), a panel of biomarkers (notably α- and β-carotene, vitamin C, lutein, zeaxanthin, and β-cryptoxanthin) should be measured as indicators of compliance in F&V intervention trials. The specific biomarker changes encountered will vary among studies that use a mixed F&V intervention, owing to differences in F&V selection when free choice is permitted.

In conclusion, increased F&V intake improved micronutrient status but had no significant effect on IR, assessed using the gold standard clamp technique, in people at high risk of CVD when body weight was maintained. It appears, therefore, that the beneficial effects of F&Vs on cardiovascular health are not likely to be directly mediated by IR. Recent evidence indicates that particular classes or types of F&Vs may have particular antidiabetic properties; hence, it is possible that benefits may only be observed in response to a more specific F&V intervention. This study supports the continued promotion of F&Vs on the basis of improving nutritional status and the overall profile of the diet but not in relation to direct improvement of IR in people at high risk of CVD.

Acknowledgments—This research was funded by the U.K. Food Standards Agency and Department of Health.

No potential conflicts of interest relevant to this article were reported.

J.V.W. carried out all assessments of IR, performed statistical analysis, contributed to the RESULTS and CONCLUSIONS, and reviewed and edited the manuscript. C.T.M. was responsible for coordinating and managing the day-to-day running of the study, including dietary assessment, dietary analysis, and nutrient status analysis; performed statistical analysis; contributed to the RESULTS and CONCLUSIONS; and reviewed and edited the manuscript. S.J.H. was a co-investigator, contributed to the conception and design of the study, oversaw the assessment of the primary end point, contributed to the RESULTS and CONCLUSIONS, and reviewed and edited the manuscript. L.L.H. assisted with participant recruitment and study execution, oversaw sample collection and storage, performed analysis of clamp samples, and reviewed and edited the manuscript. C.N.E. assisted with all assessments of IR, performed analysis of clamp samples, and reviewed and edited the manuscript. P.M.B. contributed to the RESULTS and interpretation of the data and reviewed and edited the manuscript. C.C.P. was the study statistician and supervised all statistical analysis. J.V.W. was a co-investigator, contributed to the conception and design of the study, oversaw analysis of compliance biomarkers, contributed to the discussion, and reviewed and edited the manuscript. I.S.Y. was a co-investigator, contributed to the conception and design of the study, contributed to the discussion, and reviewed and edited the manuscript. M.C.M. was the principal investigator, wrote the manuscript, and reviewed and edited the manuscript. M.C.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Parts of this study were presented in abstract form at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, Pennsylvania, 8–12 June 2012.

The authors thank Cyril McMaster and Dr. Charlotte Neville, Centre for Public Health,
Queen’s University Belfast, for assistance with laboratory analysis. The authors thank all the participants in the study for their time, interest, cooperation, and contribution to this research.

References

1. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066–3072
2. Salas-Salvadó J, Martínez-González MA, Bulló M, Ros E. The role of diet in the prevention of type 2 diabetes. Nutr Metab Cardiovasc Dis 2011;21(Suppl 2):R32–R48
3. Kastorini CM, Paragotakos DB. Dietary patterns and prevention of type 2 diabetes: from research to clinical practice; a systematic review. Curr Diabetes Rev 2009;5:221–227
4. Ylönen K, Alfthan G, Groop L, Saloranta C, Kraus WE, Svetkey LP; PREMIER study. Effect of the PREMIER interventions on insulin resistance and vascular risk: a randomized controlled trial. Diabetes 2006;55:3566–3572
5. Ford ES, Will JC, Bowman BA, Narayan KM. Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 1999;149:168–176
6. Carter P, Gray LJ, Talbot D, Morris DH, Khunti K, Davies MJ. Fruit and vegetable intake and the association with glucose parameters: a cross-sectional analysis of the Let’s Prevent Diabetes Study. Eur J Clin Nutr 2013;67:12–17
7. Azadbakht L, Mirrirmian P, Esmaiilzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005;28:2823–2831
8. Ard JD, Grabow SC, Liu D, Slentz CA, Kraus WE, Svetkey LP; PREMIER study. The effect of the PREMIER interventions on insulin sensitivity. Diabetes Care 2004;27:340–347
9. Esposito K, Marfella R, Ciottola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004;292:1440–1446
10. Salas-Salvadó J, Bulló M, Bahio N, et al.; PREDIMED Study Investigators. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011;34:14–19
11. Cooper AJ, Sharp SJ, Lentjes MAH, et al. A prospective study of the association between quantity and variety of fruit and vegetable intake and incident type 2 diabetes. Diabetes Care 2012;35:1293–1300
12. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2. Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1–v52
13. NHS Choices. Available from http://www.nhs.uk/LiveWell/SADAY/Pages/SADAYHome.aspx
14. Wareham NJ, Jakobs RW, Rennie KL, Mitchell J, Hennings S, Day NE. Validity and repeatability of the EPIC-Norfolk physical activity questionnaire. Int J Epidemiol 2002;31:168–174
15. Black RN, Spence M, McMahon RO, et al. Effect of eucaloric high- and low-sucrose diets with identical macronutrient profile on insulin resistance and vascular risk: a randomized controlled trial. Diabetes 2006;55:3566–3572
16. Bradley U, Spence M, Courtney CH, et al. Low-fat versus low-carbohydrate weight reduction diets: effects on weight loss, insulin resistance, and cardiovascular risk: a randomized controlled trial. Diabetes 2009;58:2741–2748
17. Somogyi M. Determination of blood sugar. J Biol Chem 1945;160:69–73
18. Ravussin E, Bogardus C, Schwartz RS, et al. Thermic effect of infused glucose and insulin in man. Decreased response with increased insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Invest 1983;72:893–902
19. Galgani JE, Heilbronn LK, Azuma K, et al.; Look AHEAD Adipose Research Group. Metabolic flexibility in response to glucose is not impaired in people with type 2 diabetes after controlling for glucose disposal rate. Diabetes 2008;57:841–845
20. Vuilleumier JP, Keck E. Fluorometric assay of vitamin C in biological materials using a centrifugal analyser with fluorescence attachment. J Macronut Anal 1989;5:25–34
21. Craft NE, Wise SA, Soares JH. Optimization of an isocratic high-performance liquid chromatography separation of carotenoids. J Chromatogr A 1992;589:171–176
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
23. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002;19:527–534
24. McCall DO, McCartland CP, McKinley MC, et al. Dietary intake of fruits and vegetables improves microvascular function in hypertensive subjects in a dose-dependent manner. Circulation 2009;119:2153–2160
25. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888–1904
26. McCall DO, McCartland CP, McKinley MC, et al. The effect of increased dietary fruit and vegetable consumption on endothelial activation, inflammation and oxidative stress in hypertensive volunteers. Nutr Metab Cardiovasc Dis 2011;21:658–664
27. Tuomilehto J, Lindstrom J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350
28. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
29. Boeing H, Bechthold A, Bub A, et al. Critical review: vegetables and fruit in the prevention of chronic diseases. Eur J Nutr 2012;51:637–663
30. Carter P, Gray LJ, Troughton J, Khunti K, Davies MJ. Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis. BMJ 2010;341:c4229
31. Cooper AJ, Forouhi NG, Ye Z, et al.; InterAct Consortium. Fruit and vegetable intake and type 2 diabetes: EPIC-InterAct prospective study and meta-analysis. Eur J Clin Nutr 2012;66:1082–1092
32. Liu S, Serdula M, Jankel SJ, et al. A prospective study of fruit and vegetable intake and the risk of type 2 diabetes in women. Diabetes Care 2004;27:2993–2996
33. Villegas R, Shu XO, Gao YT, et al. Vegetable but not fruit consumption reduces the risk of type 2 diabetes in Chinese women. J Nutr 2008;138:574–580
34. Wedick NM, Pan A, Cassidy A, et al. Dietary flavonoid intake and risk of type 2 diabetes in US men and women. Am J Clin Nutr 2012;95:925–933
35. National Health and Medical Research Council. Australian Dietary Guidelines. Canberra, Australia. National Health and Medical Research Council, 2013
36. Woodside JV, Young IS, McKinley MC. Fruits and vegetables: measuring intake and encouraging increased consumption. Proc Nutr Soc 2013;72:236–245
37. Stull AJ, Cash KC, Johnson WD, Champagne CM, Celafu WT. Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women. J Nutr 2010;140:1764–1768
38. Baldrick FR, Woodside JV, Elborn JS, Young IS, McKinley MC. Biomarkers of fruit and vegetable intake in human intervention studies: a systematic review. Crit Rev Food Sci Nutr 2011;51:795–815